Amicus Therapeutics (FOLD) Gross Profit (2016 - 2025)
Historic Gross Profit for Amicus Therapeutics (FOLD) over the last 10 years, with Q3 2025 value amounting to $149.6 million.
- Amicus Therapeutics' Gross Profit rose 1665.34% to $149.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $537.5 million, marking a year-over-year increase of 2099.0%. This contributed to the annual value of $475.4 million for FY2024, which is 3130.18% up from last year.
- Amicus Therapeutics' Gross Profit amounted to $149.6 million in Q3 2025, which was up 1665.34% from $139.5 million recorded in Q2 2025.
- Amicus Therapeutics' Gross Profit's 5-year high stood at $149.6 million during Q3 2025, with a 5-year trough of $59.9 million in Q1 2021.
- In the last 5 years, Amicus Therapeutics' Gross Profit had a median value of $85.4 million in 2023 and averaged $94.8 million.
- As far as peak fluctuations go, Amicus Therapeutics' Gross Profit soared by 59.84% in 2022, and later skyrocketed by 3707.23% in 2024.
- Amicus Therapeutics' Gross Profit (Quarter) stood at $74.3 million in 2021, then rose by 5.93% to $78.7 million in 2022, then surged by 31.82% to $103.8 million in 2023, then increased by 29.99% to $134.9 million in 2024, then increased by 10.92% to $149.6 million in 2025.
- Its Gross Profit stands at $149.6 million for Q3 2025, versus $139.5 million for Q2 2025 and $113.6 million for Q1 2025.